Alligator Bioscience (STO: ATORX) has announced that the first patient has been dosed in an investigator-led trial evaluating the intratumoral administration of mitazalimab, the company’s lead CD40 agonist, in patients with early-stage breast cancer.
According to Alligator, the study will evaluate mitazalimab given as a single intratumoral dose, either alone or in combination with a single intratumoral dose of the PD-1 inhibitor nivolumab, prior to surgery.
In a statement, Søren Bregenholt, CEO of Alligator, commented, “We are pleased to support this investigator-initiated trial evaluating intratumoral mitazalimab in early-stage breast cancer. Breast cancer is the most common cancer in women, and the leading cause of cancer-related death. As the biology and treatment of breast cancer varies significantly from that of pancreatic cancer this trial has the potential to generate valuable new translational insights that can guide future development to expand the clinical utility of mitazalimab.”
